Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma? by Maiwald, Bettina et al.
Is 3-Tesla Gd-EOB-DTPA-Enhanced MRI with
Diffusion-Weighted Imaging Superior to 64-Slice
Contrast-Enhanced CT for the Diagnosis of
Hepatocellular Carcinoma?
Bettina Maiwald*, Donald Lobsien, Thomas Kahn, Patrick Stumpp
Department of Diagnostic and Interventional Radiology, University of Leipzig, Leipzig, Germany
Abstract
Objectives: To compare 64-slice contrast-enhanced computed tomography (CT) with 3-Tesla magnetic resonance imaging
(MRI) using Gd-EOB-DTPA for the diagnosis of hepatocellular carcinoma (HCC) and evaluate the utility of diffusion-weighted
imaging (DWI) in this setting.
Methods: 3-phase-liver-CT was performed in fifty patients (42 male, 8 female) with suspected or proven HCC. The patients
were subjected to a 3-Tesla-MRI-examination with Gd-EOB-DTPA and diffusion weighted imaging (DWI) at b-values of 0, 50
and 400 s/mm2. The apparent diffusion coefficient (ADC)-value was determined for each lesion detected in DWI. The
histopathological report after resection or biopsy of a lesion served as the gold standard, and a surrogate of follow-up or
complementary imaging techniques in combination with clinical and paraclinical parameters was used in unresected
lesions. Diagnostic accuracy, sensitivity, specificity, and positive and negative predictive values were evaluated for each
technique.
Results: MRI detected slightly more lesions that were considered suspicious for HCC per patient compared to CT (2.7 versus
2.3, respectively). ADC-measurements in HCC showed notably heterogeneous values with a median of 1.260.561023 mm2/
s (range from 0.0760.1 to 3.060.161023 mm2/s). MRI showed similar diagnostic accuracy, sensitivity, and positive and
negative predictive values compared to CT (AUC 0.837, sensitivity 92%, PPV 80% and NPV 90% for MRI vs. AUC 0.798,
sensitivity 85%, PPV 79% and NPV 82% for CT; not significant). Specificity was 75% for both techniques.
Conclusions: Our study did not show a statistically significant difference in detection in detection of HCC between MRI and
CT. Gd-EOB-DTPA-enhanced MRI tended to detect more lesions per patient compared to contrast-enhanced CT; therefore,
we would recommend this modality as the first-choice imaging method for the detection of HCC and therapeutic decisions.
However, contrast-enhanced CT was not inferior in our study, so that it can be a useful image modality for follow-up
examinations.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide. Liver cirrhosis is a precancerous condi-
tion associated with the development of HCC. Other important
risk factors include chronic hepatitis B and C, as well as alcohol
abuse. The sequential carcinogenesis from regenerative nodules to
overt HCC has been described previously, and the de novo
development of HCC without prior liver cirrhosis has also been
delineated [1–5].
HCC can be diagnosed by various imaging modalities,
including ultrasound, multidetector computed tomography (CT)
and magnetic resonance imaging (MRI). Despite these versatile
imaging modalities, correct characterization of HCC versus other
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liver lesions remains a challenging task, and a definite diagnosis
often cannot be made based on imaging alone [6]. However, in
cancer patients, a precise diagnosis is important for optimal
treatment planning [2,7].
Concerning advanced magnetic resonance techniques, diffusion
weighted imaging (DWI) has the ability to differentiate between
malignant and benign liver lesions [8–12]. A recently developed
liver-specific contrast medium, Gd-EOB-DTPA (Gadolinium-
ethoxybenzyl-diethylene-triamine-pentaacetic-acid), is a paramag-
netic contrast agent with properties of extracellular and hepato-
biliary contrast media for use in MR imaging of the liver. This
reagent allows for dynamic perfusion imaging and the evaluation
of liver function. Gd-EOB-DTPA is taken up in hepatocytes to
approximately 50% via OATP-1 (organic anion transporter
protein-1), increasing the signal intensity of the liver parenchyma
approximately 20 min after injection [13–16]. Several studies have
demonstrated that this reagent improved the detection and
characterization of focal liver lesions [17–19].
High field-strength MRI at 3.0 Tesla provides better tissue
contrast compared to 1.5 Tesla due to a greater signal-to-noise
ratio, improved image quality, higher resolution imaging and
faster scanning times [20].
The aim of this study was to compare the diagnostic power of
CT with 3 Tesla MRI using Gd-EOB-DTPA for the diagnosis of
HCC and to evaluate the diagnostic impact of DWI with apparent
diffusion coefficient (ADC) quantification in this setting.
Material and Methods
Patient Selection
Fifty patients (mean age 60.6 years, range 29–84 years, mean
body weight 79,8 kg, range 45–120 kg, 42 male, 8 female,
Table 1) with suspected or proven HCC were included in this
prospective single-centre study to evaluate the diagnostic perfor-
mance of contrast-enhanced CT and Gd-EOB-DTPA-enhanced
MRI in terms of lesion detection. Inclusion criteria were suspicious
findings in the US or/and increased laboratory parameters (e.g.,
alpha-fetoprotein). Exclusion criteria were renal failure, allergy to
contrast agents, hyperthyreoidism, pregnancy and, especially for
the MRI-examination, pacemaker or other non-compatible
implants and claustrophobia. The aetiology of liver cirrhosis in
the patient cohort was as follows: 26 patients with alcohol induced
liver cirrhosis, 2 with Hepatitis B- and 3 with Hepatitis C-related
chronic liver disease, 3 patients with hemochromatosis, one with
Budd-Chiari-Syndrome and one with non-alcoholic steatohepati-
tis. 14 patients had cryptogenic liver cirrhosis. Based on the Child-
Pugh-Classification, the severity of liver cirrhosis was classified as
class A in 27 patients, class B in 16 patients and class C in 7
patients [Table 1].
The histopathological report after resection or biopsy of a lesion
served as the gold standard for diagnosis, whereas a surrogate of
follow-up (after 6 months) or complementary imaging technique
(ultrasound, digital subtraction angiography) in combination with
clinical (loss of weight, general state) and paraclinical parameters
(especially alpha-fetoprotein) was used in unresected lesions.
This study was approved by the ethics committee of the medical
faculty of the University of Leipzig, and all patients provided
written informed consent.
Imaging technique
Multiphase-CT was performed using two different scanners
(Brilliance 64/iCT; Philips Healthcare, Eindhoven, Netherlands)
with identical parameters to prevent bias within the CT:
collimation of 0.625 mm, rotation time of 0.75 s, tube voltage of
120 kV, tube current 200 mAs and adjusted with automatic dose
modulation, reconstructed slice thickness of 3 mm, matrix
512*512). The contrast agent (Iopromide Ultravist 370, Bayer
Vital GmbH, Leverkusen, Germany) was applied at a constant
volume of 100 ml at a rate of 3 ml/s (Power injector mississippi,
Ulrich Medical, Ulm, Germany). The unenhanced phase, early
arterial phase 10 s after bolustracking (positioning the respective
region of interest in the abdominal aorta just above the coeliac
trunk, threshold 150 HU) and portal venous phase 60 s after
reaching the threshold were acquired.
Subsequent MRI (median time: 2.2 days, range 0–30d) was
performed in all subjects using a 3.0 Tesla scanner (TrioTim,
Siemens Medical Solutions, Erlangen, Germany). The study
protocol consisted of the following sequences:
(1) T2w-HASTE (half-fourier acquisition single-shot turbo spin
echo) coronal and axial
(2) T1w-VIBE (volume-interpolated breath-hold examination)
coronal unenhanced, axial unenhanced and dynamic after
contrast medium was applied (Gd-EOB-DTPA (Primovist),
Bayer Vital GmbH, Leverkusen, Germany) at 0.1 ml/kg
bodyweight at a rate of 2 ml/s using a power injector
(Spectris solaris EP, Medrad, Dusseldorf, Germany),
followed by a 30 ml saline flush. Scanning times were as
follows: arterial phase, 2 s; portalvenous phase, 30–40,
equilibrium phase, 2–3 min; and hepatobiliary phase,
20 min after the contrast bolus reached the abdominal
aorta.
(3) Diffusion-weighted sequence coronal and axial (b-value 0,
50 and 400 s/mm2)
(4) T2w TSE (turbo spin echo) with fat saturation coronal
(5) T1w in phase and opposed phase axial
See Table 2 for more details concerning the sequences.
Imaging analysis
Image analysis focused on the number, size and detectability of
liver lesions, as well as image quality. A radiologist with 10 years of
experience in abdominal imaging performed the analysis using a
picture archiving and communication system workstation (Magic-
View 1000, Siemens Medical Solutions, Erlangen, Germany). The
observer was aware of the patients being at risk of HCC, but
otherwise blinded to all patient data. Diagnosis of HCC was based
on hypervascularization in the arterial phase and washout in the
portal venous phase or delayed phase, as suggested by the
European Association for the Study of the Liver and the American
Association for the Study of Liver Disease for MRI and CT [1]. In
addition, focal areas with a suspicious hypointense signal in the
hepatobiliary phase were used to detect HCC [21] (Figure 1). The
radiologist recorded the presence and anatomical location of
lesions, as well as diagnostic confidence using the following 5-point
scale: 1 = definitely not HCC, 2 = probably not HCC, 3 =
equivocal, 4 = probably HCC, 5 = definitely HCC.
Lesion detectability and image quality were evaluated using a 5-
point rating-scale (1 = excellent, 2 = good, 3 = fair, 4 = poor, 5 =
unacceptable). The average largest tumour diameter was deter-
mined using a measuring tool integrated in the workstation
software.
ADC-values were measured for each clearly demarcated lesion
in ADC-map by drawing a circular region of interest into the
tumour that encompassed as much of the lesion as possible while
excluding vascular structures and necrotic tissue.
Imaging analysis was accomplished according to the following
settings:
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1) In general, CT-scans were compared with
2) complete MRI-examinations (including conventional dynam-
ic MRI with hepatobiliary phase and DWI).
To estimate the impact of the hepatobiliary phase and diffusion-
weighted imaging, MRI-data were subdivided into three sets:
3) conventional dynamic MRI without the hepatobiliary phase
and DWI
4) dynamic MRI including the hepatobiliary phase
5) MRI including diffusion-weighted sequences.
In addition, the observer evaluated the reading time.
Statistical analysis
Statistical analysis was performed using SPSS 20.0 for Windows
(statistical package for social sciences 20.0, Chicago, IL, USA) and
Microsoft Excel (Microsoft, Redmond, WA, USA). The diagnostic
performance of each technique was assessed by measuring the area
under the curve (AUC) of the free-response receiver operating
characteristic analysis (ROC-curve) on a lesion-per-patient-basis.
Sensitivity, specificity, and positive and negative predictive
values were calculated for patients assigned a diagnostic
confidence level of 4 and 5 (probably and definitely HCC). In
addition, we included patients with a confidence level of 3, because
in clinical routine, a suspicious lesion must be clarified (e.g., by
further imaging or biopsy). The differences in the ROC-curves,
sensitivities, specificities, positive predictive value (PPV) and
negative predictive value (NPV) were statistically analysed using
a binomial test. Student’s t-test was used to calculate significant
differences for image quality, detectability and reading time
between the image modalities, P-values ,0.05 were considered
significantly different.




Mean age (years) 60.6 (range 29–84)
Mean weight (kg) 79.8 (range 45–120)













Table 2. MR Imaging Parameters.
Parameter T2-weighted (HASTE) T1-weighted (VIBE) DWI T2-weighted TSE
T1-weighted in and out
of phase
Imaging plane Coronal and axial Coronal and axial
unenhanced, axial
enhanced
Coronal and axial Coronal Axial
Fat saturation No Yes Yes Yes No
Respiratory triggering Breath-hold (12 s) Breath-hold (16 s) Respiratory-triggered Respiratory-triggered Breath-hold (18 s)
Repetition time (TR) 800 ms 2.92 ms 2000 ms 2000 ms 212 ms
Echo time (TE) 83 s 0.86 ms 60 ms 81 ms 2.32 ms
Flip angle 160u 10u - 120u 65u
Bandwidth 781 Hz/Px 540 Hz/Px 1736 Hz/Px 260 Hz/Px 930 Hz/Px
Field of view (FOV) 450 mm 400 mm 380 mm 400 mm 380 mm
Slice thickness 5 mm 3 mm 5 mm 5 mm 5 mm
Matrix 320*256 256*200 192*154 320*224 256*200
doi:10.1371/journal.pone.0111935.t002
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Results
In 35 of 50 patients, the histopathological report after resection
or biopsy of a lesion served as the gold standard for diagnosis, and
in 24 of these 35 patients, the diagnosis of HCC was proven
histopathologically. In 2 additional cases, HCC was diagnosed at
follow-up (after 6 months) via clinical and paraclinical parameters.
In our study, 26 of 50 patients were positive for HCC (MRI-
related: 9 patients with one lesion, 4 patients with 2 lesions, 3
patients with 3 lesions and 10 patients with 4 or more lesions).
ROC-curves for MRI displayed similar AUCs as observed for
CT (0.837 vs. 0.798, p = 0.48). Sensitivity and positive and
negative predictive values were measured for both methods
(sensitivity 92%, PPV 80% and NPV 90% for MRI vs. sensitivity
85%, PPV 79% and NPV 82% for CT). Specificity was 75% for
both techniques (see Table 3 and Figure 2). False positives resulted
from numerous metastases of a neuroendocrine carcinoma, one
adenoma and regenerative nodules. Because we calculated
sensitivity, specificity, and positive and negative predictive values
on a per-patient-basis, our subset analyses revealed no differences.
On a liver-lesion-per-patient basis, we detected slightly more
lesions that were suspicious for HCC using MRI compared to CT,
but this value did not reach statistical significance (mean, 2.7 for
MRI versus 2.3 for CT, p = 0.256, Figure 3). One additional HCC
was identified with aid of the hepatobiliary phase compared to
conventional dynamic MRI; this lesion measured 8 mm in
diameter (Figure 4). Compared to Gadolinium-EOB-DTPA-
enhanced MRI-images evaluated with the hepatobiliary phase,
no additional lesions were detected by DWI. However, DWI
identified one additional malignant lesion compared to conven-
tional dynamic MRI-scan. This was the same 8 mm diameter
lesion that was observed with the hepatobiliary phase, and this
finding impacted patient treatment (Figure 4).
Lesion size was similar using both methods, with an average
greatest diameter of 33 mm for CT and 32 mm for MRI
(measured in the arterial phase T1w VIBE; p = 0.195). Twenty
malignant neoplasms were .3 cm, 16 lesions were 2–3 cm and 35
lesions were ,2 cm, as determined by MRI-scans.
ADC-measurements in 32 lesions showed extremely heteroge-
neous values, with a mean of 1.260.561023 mm2/s (range,
0.0760.1 to 3.060.161023 mm2/s; Figure 5).
The radiologist reported that the detectability of lesions was
similar using both methods using a 5-point rating scale (2.6 for CT
and 2.7 for MRI, p = 0.807; range from 2.6 to 4.0 between
sequences, 1 = excellent, 5 = unacceptable). The ability of MRI to
detect lesions was significantly better using the hepatobilary phase
(2.2, range from 1 to 4) compared to conventional dynamic MRI
(2.9, p = 0.005), but the difference was not significantly different
compared to DWI (2.6, p = 0.125).
Image quality (2.2 for CT vs. 2.3 for MRI, p = 0.249, 2 = good,
3 = fair) was more scattered within MR sequences (1.8 in T1w
HASTE and 2.9 in T2w TSE). Image quality was rated better for
the hepatobiliary phase and conventional dynamic MRI than for
DWI (2.0 for hepatobiliary phase, 2.1 for dynamic MRI without
hepatobiliary phase and 2.7 for DWI, p,0.001). No significant
disparity was noted between conventional dynamic MRI and the
hepatobiliary phase (p = 0.342).
Figure 1. A 59-year-old male patient with liver cirrhosis (Child A) and HCC (arrow) in segment 7. Axial images: A) lesion is barely visible
using unenhanced T1w-VIBE, B) marked arterial enhancement in T1w-VIBE following i.v. administration of contrast medium, C) typical washout of the
lesion in the equilibrium phase (T1w-VIBE), and D) a clear hypointense lesion in the hepatobiliary phase (20 min after contrast agent injection, T1w-
VIBE). Similar behaviour was observed with typical contrast medium enhancement in CT: E) early arterial phase after bolus tracking and F) washout in
the portal venous phase with pseudocapsule.
doi:10.1371/journal.pone.0111935.g001
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The average reading time for MR-images was16.9 min and
significantly longer than the reading time for CT-scans, which
averaged 4.5 min. (p,0.001).
Discussion
Accuracy
In our study, MRI showed similar diagnostic accuracy for the
detection of HCC compared to CT. Reports by Akai et al. and
Lee et al. demonstrated similar results with a tendency to higher
diagnostic accuracy for MRI, but also without statistically
significant differences [22,23]. One explanation for this discrep-
ancy might be the high number of suspicious lesions with a
diameter greater than 3 cm in our study population. Haradome et
al. also showed no difference in diagnostic accuracy between
conventional dynamic MRI and CT. However, using the
hepatobiliary phase, MRI displayed significantly higher accuracy
than CT, especially for lesions smaller than 1.5 cm [24]. Kim
demonstrated that MRI has better sensitivity for the detection of
HCCs due to an increased delineation of hypointensity of HCC at
a three-minute late phase and a hepatocyte phase [25], supporting
previous reports [26–28]. While these studies report that CT is
inferior to MRI, the use of different contrast agents, older scanner
technology and different scanning parameters of the CTs must be
taken into account. Similar to our study parameters, several
groups used an early arterial phase [25,27]. For example, Chan et
al. described better conspicuity for hepatocellular carcinomas
using a bolus tracking delay of 6s for achieving the arterial phase
[29]. Other studies state that the late arterial phase (e.g.,
approximately 14–30 s from 100 HU-threshold) is the optimal
scan window for the detection of HCC [30]. Moreover, differences
in histopathological subtypes of HCC might also yield different
enhancement patterns [31], making it difficult to clearly specify
standard examination protocols.
Detectability and number of lesions
Although the reader rated the subjective detectability of liver
lesions similarly for MRI and CT, slightly more liver lesions per
patient were detected using 3T MRI. Although this did not reach
statistical significance, it is important for therapeutic decisions
because liver transplantation can achieve excellent results in
patients with HCC according to the benchmark defined by the
Milan criteria (solitary HCC of less than 5 cm or with up to three
nodules of less than 3 cm) [32–34]. Furthermore, decision to
surgically resect tumours or use minimally invasive therapies (i.e.,
radiofrequency ablation (RFA), laser-induced interstitial thermo-
therapy (LITT), microwave ablation (MWA), cryoablation and
transarterial chemoembolisation (TACE), etc.) depends on num-
ber and size of hepatocellular carcinomas, as visualised using CT
or MRI [35,36].
In our study, the detectability of lesions using MRI with the
hepatobiliary phase 20 min after i.v. injection of Gd-EOB-DTPA
was significantly better than conventional dynamic MRI. In one
patient a suspicious lesion with a diameter of 8 mm was only
observed with the hepatobiliary phase and DWI, but not with
conventional dynamic MRI (Figure 4). This lesion changed the
therapeutic management of the patient because it was the 4th
HCC suspicious lesion in his liver, which excluded him from the
liver transplantation list according to the Milan criteria [32].
These data support several studies reporting that Gd-EOB-DTPA
enhanced MRI is superior to conventional dynamic MRI
[17,21,24].
Gd-EOB-DTPA is a gadolinium-based, liver specific MRI
contrast medium that allows diagnosis derived from haemody-
namics during the extracellular phase and measures hepatocellular
function during the hepatobiliary phase. Information regarding
the degree of cellular differentiation might also be possible [18].
Concerning the timing of hepatobiliary phase imaging, Motosugi
Table 3. Diagnostic accuracy, sensitivity, specificity, PPV and NPV for MRI and CT (binomial test, p,0.05 = significant).
MRI CT P-value
Diagnostic accuracy (AUC) 0.837 0.798 0.4795
Sensitivity 0.92 0.85 0.4795
Specificity 0.75 0.75 1.000
PPV 0.80 0.79 0.500
NPV 0.90 0.82 1.000
doi:10.1371/journal.pone.0111935.t003
Figure 2. Flow chart for identification of patients with HCC in MRI and CT.
doi:10.1371/journal.pone.0111935.g002
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et al. described that if the liver parenchyma is sufficiently
enhanced 10 min after injection, no further imaging is necessary
to detect focal liver lesions. However, the visual liver to spleen
contrast scores 20 min after injection were frequently higher than
10 min images in patients with chronic liver diseases. These data
indicate that a longer delay of 20 min might be more useful for
patients with chronic liver diseases [37]. Because all of our patients
suffered from chronic liver disease, we acquired hepatobiliary
phase images 20 min after contrast application.
DWI
DWI is commonly used in liver imaging to assess various focal
lesions. In particular, DWI has a higher detection rate and
diagnostic performance for small, malignant liver lesions com-
Figure 3. A 59-year-old male patient with liver cirrhosis and HCC (arrow) in S3 was only observed using MRI: A) markedly
hyperintense HCC in T2w-HASTE axial, B) typical arterial enhancement in T1w-VIBE, and C) hypointense lesion in the hepatobiliary
phase. No lesion was detected using CT: D) early arterial phase and E) portal venous phase.
doi:10.1371/journal.pone.0111935.g003
Figure 4. MRI of a 53-years-old male patient with HCC (arrow) in Segment 5: no lesion was identified in the arterial (A) and
equilibrium phases (B), a small hypointense lesion was only observed in the hepatobiliary phase (C) and in DWI, where it is seen as
a hyperintense lesion in b 50- (D) and b 400-images (E) and hypointense in the ADC-map (F).
doi:10.1371/journal.pone.0111935.g004
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pared to conventional dynamic MRI with different contrast
agents; however, these results are not always significant [38–40]. A
recent study by Holzapfel et al. reported no significant difference
in diagnostic accuracy and sensitivity between diffusion weighted
imaging, Gd-EOB-DTPA-enhanced imaging and combined im-
aging for the detection of focal liver lesions. However, for lesions
smaller than 10 mm, a combination of DWI and Gd-EOB-DTPA
significantly increased the overall detection rate. Similar to our
findings regarding HCC-related diagnostic accuracy, Gadolinium-
enhanced MRI and the combination of DWI and Gd-EOB-DTPA
enhanced MRI demonstrated equal results [41]. In our 50
patients, just one additional HCC suspicious lesion was detected
with DWI compared to conventional dynamic MRI, an 8 mm
lesion that was also detected with hepatobiliary phase imaging.
Therefore, DWI did not improve the detection of HCC compared
to imaging with Gd-EOB-DTPA in our study.
Park et al. also demonstrated that DWI was outperformed by
contrast enhanced T1-weighted imaging for the detection of HCC,
but it represents a reasonable alternative [42]. However, if Gd-
EOB-DTPA is used in the hepatic imaging, a time gap occurs
between the equilibrium phase and the hepatobiliary phase, and
because there is no significant impact of contrast media on
achieving diffusion-weighted imaging and ADC-maps [43–45].
This gap can easily be filled with respiratory-triggered, diffusion-
weighted imaging, which can provide additional information for
the characterization of focal liver lesions. An important advantage
of DWI is that no contrast agent is necessary, a property that is
especially valuable for patients with poor renal function [39]. In
our department, diffusion-weighted MR imaging is part of the
routine liver protocol for all patients.
The potential to differentiate between benign and malignant
liver lesions using ADC-quantification was previously reported in
the literature [8–12]. Several thresholds have been proposed to
accomplish this task, but there is still considerable overlap between
benign and malignant liver lesions [9]. Vandecavaeye confirmed
that there is no significant difference in ADC between malignant
and benign lesions in patients with cirrhotic liver disease [46]. In
our study, the mean ADC-value of HCC lesions was
1.260.561023 mm2/s, which is similar to values reported in the
literature. For example, Naoto measured an ADC-value of
1.3160.2861023 mm2/s [12], and Holzapfel reported an ADC-
value of 1.1260.2861023 mm2/s for a small number of HCC
samples [9]. These variances are likely due to differential
cellularity of the tumours [47]. Another influential factor are the
b-values chosen for DWI. In our study, we used relatively low b-
values (b = 0, 50 and 400 s/mm2), which have the disadvantage of
being influenced by perfusion effects. Measured ADC-values tend
to decrease as the b-value increases [48]. However, the use of low
(perfusion-sensitive) b-values has several advantages: it provides a
higher signal-to-noise ratio and more anatomical information of
the liver, it is less sensitive to eddy current-induced distortions and
it suppresses signals from the hepatic vasculature, which improves
the detectability of perivascular lesions [49–51]. Further investi-
gations are needed to determine the best b-values for liver
imaging.
Our study has some limitations. First, there was a bias in patient
recruitment because we included patients with proven or suspected
HCC. This stipulation might result in an overestimation of
specificity. Second, we could not achieve a histological proof for
every detected lesion due to ethical reasons, so we had to use
follow-up examinations and surrogates of clinical and paraclinical
findings to confirm the presence of lesions. For this reason, we
calculated sensitivity, specificity, and positive and negative
predictive values on a patient basis. Third, our study group was
relatively small, and further studies with more patients might yield
statistically significant results. Fourth, we used a first generation
MR-scanner with 3 Tesla, which can suffer from B0 artefacts
within the liver parenchyma. Newer MR-Scanners with different
coil and RF impulse designs (i.e., the TrueForm and Multi-
Transmit) reduce these artefacts and can increase the diagnostic
ability for liver imaging. Finally, we only determined ADC-values
for suspicious lesions that were clearly visible in the ADC-map.
However, our ADC-values were comparable to the values given in
literature.
Conclusions
Our study did not show a statistically significant difference in
detection of HCC between 3-Tesla Gd-EOB-DTPA-enhanced
MRI with diffusion-weighted imaging and 64-slice contrast-
enhanced CT.
As we detected slightly more lesions per patient using MRI, we
recommend this imaging modality as the first-choice imaging
method for the detection of HCC and individual therapeutic
decisions. However, contrast-enhanced CT was not inferior in our
study, indicating that it represents a useful image modality when
MRI is not available or for follow-up examinations.
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